OTLK
MaterialsOutlook Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving OTLK Today?
No stock-specific AI insight has been generated for OTLK yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
OTLK News
20 articles- Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingYahoo Finance·Apr 23, 2026
- Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesYahoo Finance·Apr 22, 2026
- Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)Yahoo Finance·Apr 21, 2026
- Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDAYahoo Finance·Apr 7, 2026
- Outlook Therapeutics Announces Closing of $5.0 Million Public OfferingYahoo Finance·Mar 25, 2026
- Outlook Therapeutics Announces Pricing of $5.0 Million Public OfferingYahoo Finance·Mar 24, 2026
- Outlook Therapeutics Announces Proposed Public OfferingYahoo Finance·Mar 23, 2026
- Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible NoteYahoo Finance·Mar 16, 2026
- Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)Yahoo Finance·Mar 5, 2026
- Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in SwitzerlandYahoo Finance·Feb 19, 2026
- Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·Feb 17, 2026
- Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 17, 2026
- Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response LetterYahoo Finance·Feb 11, 2026
- OTLK Stock Crashes 67% in a Week: Here's What You Need to KnowYahoo Finance·Jan 7, 2026
- Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business DevelopmentYahoo Finance·Jan 6, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Jan 2, 2026
- BC-Most Active StocksYahoo Finance·Jan 2, 2026
- US Equity Futures Rise Friday at Start of New Year Following Lead of European MarketsYahoo Finance·Jan 2, 2026
- Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinksYahoo Finance·Jan 2, 2026
- FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present formYahoo Finance·Jan 1, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Outlook Therapeutics Inc
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.